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age annual costs were estimated by health service and patient. Costs were adjusted 
for inflation and expressed in 2014 US dollars. RESULTS: The prevalence of BC was 
247.72 per 100,000 members, the average age was 58.86 years (SD 13.05 years), cit-
ies with higher concentrations of patients were Bogotá (35.08%), Medellin (10.65%), 
and Barranquilla (9.67%). The average annual cost of health care for 1314 patients 
was $ 5,709,078.15, given mainly by chemotherapy with 31.36%, followed by drugs 
(27.34%), radiotherapy (7.48%), hospital surgery (6.26%), diagnostic and therapeu-
tic procedures (3.55 %) and hospitalization (3.22%). The average annual cost per 
patient was $ 8350.95 (2010), $ 7798.91 (2011), $ 6719.66 (2012), $ 5910.49 (2013) and 
$ 5214.47 (2014). CONCLUSIONS: The average annual cost per patient with BC in 
an insured population in Colombia is equivalent to the annual premium per capita 
of 17 patients by 2014. I an average decrease in cost per patient of 38% was found 
during the follow.
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OBJECTIVES: Simple contact dermatitis (CD) and pressure ulcers (PU) of immobi-
lized patients with urinary is an important and not enough explored clinical and 
economic problem in hospitals and social care organizations. METHODS: An obser-
vational clinical and economic study of a typical practice of CD and PU. In the study 
taken forms of 85 patients, analyzed in 7 critical points each. Patients had a higher 
risk of CD and PU. The average age - 76 ± 5,6 years. RESULTS: Patients without CD 
and PU - 25 persons (29.8%), with PU 50 persons (58.8%), with CD 35 persons (41.1%). 
In 19 patients (22.4%) had and PU and CD in various critical areas. CD was marked in 
75 points (12.6%), PU 1-2st - 93 points (15.6%), PU 3-4st - 8 points (1.3%). Total costs 
in rubles (1$ US = 34 ₷) for 1 patient in the group without the CD and PU were 12895, 
drugs -325, on care products -391, for services -12179. In the group “PU 1-2st” total 
costs 13546, on drugs -267, at the expense of care -769, for services -12510. In the 
group “PU 3-4st “ total costs 25290, on drugs –161, on care products -4356, for services 
- 20 773. In the group of “KD” total costs 16027, on drugs -146, on care products 1349, 
for services – 14532. CONCLUSIONS: The frequency of PU is 58.8%, KD - 41.1%, KD 
and PU - 22.4%. Without CD and PU - 29.8%. Total costs are the biggest in group of 
patients with high degrees of PU, due to the high cost of services and care products. 
Drug costs are not high. A high cost in the CD group is associated with services and 
care. The data will be used to construct a Markov model.
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OBJECTIVES: Colorectal cancer (CRC) is considered as the third common cancer 
among men and the second common cancer among women worldwide. In Vietnam, 
colorectal cancer is the fifth common cause of cancer - related incidence. In many 
countries, economic burden of colorectal cancer has been investigated logically. 
However, there have not had any research about this in Vietnam. This research was 
conducted to provide more detail information to help the decision-makers find out 
the most appropriated policies to control the disease. METHODS: The economic bur-
den of CRC in Vietnam was evaluated by the following formula: C = ∑Pi x COIi.; in 
which, C: economic burden of CRC in Vietnam, Pi: number of patients in stage i of CRC 
in Vietnam, COIi: cost of CRC in stage i. RESULTS: The 5-year prevalence of CRC is 27.3 
per 100,000. The economic burden of CRC of the whole society was estimated about 
14,268.3 billion VND. The values fluctuated sharply from stage I to stage IV, accounted 
for 6.9 billion VND; 5,731.2 billion VND; 3,564.5 billion VND and 4,965.7 billion VND, 
respectively. As lots of patients were diagnosed at stage II (about 38%), the economic 
burden of this stage was predominant (40%) compared to the others. Furthermore, 
in all stages except stage I, the economic burden related to medicine was much more 
higher than that of medical services. CONCLUSIONS: The high economic burden 
of CRC should be considered to conduct relevant healthcare policies, especially for 
patients in advanced stages. Key word: economic burden, colorectal cancer.
PHS44
mediCal Care CoStS of CHiKungunya ViruS infeCtion in a PediatriC 
PoPulation in Colombia
Castañeda-Orjuela C.1, Díaz-Jiménez D.1, Rodríguez-Castillo L.1, Paternina-Caicedo A.2, 
Pinzón-Redondo H.3, Alvis-Guzman N.2, De la Hoz-Restrepo F.1
1Instituto Nacional de Salud, BOGOTA D.C., Colombia, 2Universidad de Cartagena. Centro 
de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, 
Colombia, 3Hospital Infatil Napoleón Franco Pareja, Cartagena., Colombia
OBJECTIVES: In 2013 December, PAHO confirmed the local circulation of chikungu-
nya virus (CHKV) in the region. In 2014 September Colombia reported the first local 
CHKV case in the Bolívar, and started an outbreak within a susceptible population. 
The objective of this analysis is to estimate the medical care cost of children patients 
with suspect of CHKV attended at a reference pediatric Hospital in Cartagena-
Bolivar, at the start of the CHKV local transmission in Colombia. METHODS: A ret-
rospective bottom-up cost analysis was designed. We selected randomized sample 
of clinical records from children patients with CHKV clinically suspected during 
September – November 2014 at the Hospital “Napoleón Franco Pareja” in Cartagena 
city, Colombia. A costing data collection instrument was designed a piloted to col-
lect the information about the frequency of use activities and supplies by patient. 
Administrative and cost data by patient and activity were obtained from the 
Hospital. Costing items included: consults, hospitalization bed-day, supplies, drugs, 
and diagnosis and therapeutic procedures. Total cost per cost item and patient were 
estimated and average cost per patient reported. Costs were expressed in 2014 USD 
with an Exchange rate of 2392.46 COP per American dollar. RESULTS: A sample of 
conducted based on the perspective of healthcare payers; therefore, only medical 
direct cost was evaluated. The cost of medical service and drugs were retrieved 
from the price-list of relevant medical services and drugs, registered by Ministry of 
Health in Vietnam 2012. RESULTS: The average direct cost of CRC for one patient 
accounted for nearly 756.83 million VND per year. Cost for one patient increased 
with the increasing of disease severity and accounted for 1.875 million VND; 800 mil-
lion VND; 822 million VND and 1,351 million VND in stage I, II, III, IV, respectively. In 
the structure of cost, with the increase in severity of disease, the percentage of drug 
cost increased and the percentage of medical services decreased. CONCLUSIONS: 
The cost of CRC treatment increased following the increase of disease severity. The 
huge economic impact of CRC should be controlled and considered to conduct the 
proper healthcare policies.
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OBJECTIVES: To examine the association of direct medical costs with clinical and 
health characteristics in visually impaired individuals in Singapore. METHODS: 
We prospectively recruited 500 visually impaired individuals due to cataract, glau-
coma, diabetic retinopathy (DR), or age-related macular degeneration (AMD) from 
Singapore National Eye Centre. In face-to-face interviews, vision function and health 
status of the individuals were assessed using the 14-item Visual Functioning (VF-14) 
and EQ-5D questionnaires, respectively. Severity of visual impairment (VI) and direct 
medical costs were determined using clinical and billing data, respectively, in the 
study center. Annual medical costs per capita were estimated and compared for 
individuals with different eye diseases and in different levels of VI, vision function, 
and health status using generalized linear models. RESULTS: The mean (standard 
deviation [SD)] age of participants was 71.6 (9.8) years old. The proportion of male 
was 47.6% and the mean (SD) presenting visual acuity was 0.49 (0.31). The annual 
medical costs per capita were S$6.8K. After adjusting for socio-demographics, the 
annual medical costs differed in individuals with different eye diseases (AMD 
higher than cataract by S$13.1K, glaucoma by S$9.2K, and DR by S$12.4K), VI sever-
ity (between mild/moderate and severe VI: S$8.8K), vision function (between absence 
and presence of problems: S$3.7K), and health status (between absence and pres-
ence of problems: S$1.3K). CONCLUSIONS: Direct medical costs are highest in AMD 
individuals and are associated with clinical measure and vision function in visually 
impaired individuals in Singapore.
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OBJECTIVES: Vaccination against influenza, pneumococcal disease and herpes zos-
ter are recommended for the elderly, who have high morbidity and mortality rates 
due to these three diseases. Many studies investigated the clinical burden by each 
vaccine-preventable disease; however, empirical data on the full economic burden 
of adult vaccine-preventable diseases is scarce. This study examines the healthcare 
resource utilization and medical expenditures of elderly with vaccine-preventable 
diseases in Taiwan. METHODS: We included 104,273 beneficiaries aged 65 years or 
older under the Taiwan’s National Health Insurance program in 2010. Patients with 
vaccine-preventable diseases were defined as those who had at least one diagno-
sis of flu, pneumococcal disease, or herpes zoster. Outcomes of interest include 
healthcare resource utilization (inpatient, outpatient, and emergency department 
(ED) visits) and associated medical expenditures. RESULTS: In 2010, there were 
6.77%, 3.18% and 1.88% of elderly population had been diagnosed and received 
ambulatory care for pneumonia, flu and herpes zoster, respectively. However, on 
average, patients with pneumonia, flu, herpes zoster visited the doctor’s office 36.9, 
37.3, 38.5 times (without those diseases: 26.7 times), respectively. The healthcare 
resource utilization from patients with vaccine-preventable diseases attributed to 
large proportion of medical expenditures. Among annual medical expenditures 
for the elderly (US$0.2 billion), 13.08% of expenditures cost from pneumonia care, 
3.10% from flu and 2.53% from herpes zoster. Average cost per patient were US$3.6 
thousand, US$1.8 thousand and US$ 2.5 thousand for pneumonia, flu and herpes 
zoster, respectively. CONCLUSIONS: This study demonstrates significant burden of 
healthcare utilization caused by older people with vaccine-preventable diseases. In 
addition, different management strategies may be warranted for different vaccine-
preventable diseases since the differences of patient characteristics as suggested 
by our study.
PHS41
direCt CoStS of HealtH Care for breaSt CanCer, tHe CaSe of a HealtH 
manteinanCe organization in Colombia
Moreno JA1, Muñoz-Galindo IM1, Guarin NE1, Diaz JA2, Arevalo HO1
1Salud Total EPS, BogotÃ¡ D.C., Colombia, 2Universidad Nacional de Colombia, BogotÃ¡ D.C., 
Colombia
Breast cancer (BC) is one of leading causes of death in women and is also considered 
a catastrophic illness associated with a large financial burden on the health system 
with incremental trend.OBJECTIVES: To estimate the direct costs associated with 
the health care of patients with BC affiliated with a health manteinance organiza-
tion (HMO) in Colombia during the period 2010-2014. METHODS: A retrospective 
cross-sectional study was conducted in a cohort of 1314 patients with BC affiliated 
with a HMO in Colombia and distributed in 16 cities of the country, in the period 
2010 to 2014. Demographic characteristics of the cohort are described and the aver-
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criteria, of which 3,152 (15.1%) underwent additional diagnostic imaging in the 6 
months post-index. White women were 1.12 times more likely to be recalled than 
African-American women (p< 0.001). Average costs per patient recalled were $838 
among white women and $804 among African-American women. Overall, 28.6% 
of costs were from additional imaging (diagnostic mammography and/or ultra-
sound), 39.2% were from guided biopsy procedures, and 24.4% from open biopsy. 
Recall-related office visits, MRI, fine needle aspiration, and ductogram accounted 
for < 5% of recall costs. Individual recall procedure rates were substantively simi-
lar between White and African-American recalled patients but African-American 
women had higher per-patient imaging costs and lower per-patient open biopsy 
costs. CONCLUSIONS: Improving breast cancer screening with a more accurate 
mammogram may significantly reduce Medicaid costs as approximately one-in-six 
women undergo additional diagnostic imaging following a screening mammogram 
with substantial associated costs. Recall rate and costs varied by race.
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OBJECTIVES: To describe the burden of recall following traditional screening mam-
mography from the perspective of US self-insured employers. METHODS: The 
Truven Health MarketScan Commercial and Health and Productivity Management 
Databases were used to identify female employees aged 40-65 years undergo-
ing screening mammography (index event) in 2010-2012 with at least 12 months 
pre- and 6 months post-index continuous enrollment; patients with a breast 
cancer diagnosis in the pre-index period were excluded. Recall was defined as 
receipt of diagnostic mammogram or ultrasound in the six months following the 
index screen. Employer cost per recall (2013 US$) was the sum of breast-related 
imagining procedures and associated diagnostic procedure costs in the 6 months 
post-index, excluding patient payments and breast cancer treatment costs. 
Absenteeism costs were calculated using a wage constant ($38/hour). RESULTS: 
Of the 339,912 patients who met the study criteria, 47,321 (13.4%) underwent 
additional diagnostic imaging within 6 months post-index with an average direct 
medical cost to employers of $1,279 per patient recalled. Nearly one-fourth (23.4%) 
of recall costs was attributable to additional imaging (diagnostic mammography 
or ultrasound), 40.0% was attributable to guided biopsy and 28.0% attributable to 
open biopsy. One-fifth (21.9%) of recalled patients had at least two days with recall-
related procedures while 4.2% had at least three recall event days. Absenteeism 
costs were $948 in the 30 days following recall among patients with absenteeism 
claims (67.2%), increasing to $4,472 over 6 months post-recall among patients with 
absenteeism claims (81.9%). Short-term disability claims increased following recall 
(4.0% vs. 4.4%, p< 0.01), with an average cost per claim of $10,849. CONCLUSIONS: 
Recall following traditional mammography represents a significant cost burden to 
employers with nearly one-in-six female employees with a new screening mam-
mogram undergoing additional diagnostic imaging and associated procedures. 
Strategies to reduce the burden of recall should not ignore indirect employer 
costs.
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OBJECTIVES: Current cost studies describing people with epilepsy do not segment 
the populations by seizure type. This paper produces an economic model of people 
experiencing seizures, including individuals with epilepsy, broken into novel cat-
egories useful in assessing the potential effect of future interventions. METHODS: 
Three-year’s worth of administrative claims data from Milliman’s commercially-
insured research dataset (n= 16.8 million 2012) was grouped into benefit service 
cost categories. Individuals experiencing seizures were extracted whose coverage 
included prescription drugs and whose medical claims contained the following 
ICD9CM diagnosis codes: 345.00, 345.01, 345.10, 345.11, 345.2, 345.3, 345.40, 345.41, 
345.50, 345.51 and 780.33. Individuals were grouped into three novel categories: 
Motor Seizures (345.10, 345.11, 345.3, 345.40, and 345.41), Post Traumatic Seizures 
(780.33) and Non-Motor Seizures (345.00, 345.01, 345.2, 345.50, and 345.51). RESULTS: 
Individuals experiencing seizures represented 0.4% of the population and accounted 
for 1.8% of allowed claims dollars. The odds of being admitted to the hospital for 
the Motor and Non-Motor Seizure groups were 5.5 and 4 times higher, respectively, 
with a 2-day longer average length of stay and total allowed claims dollars were 
5 and 4.2 times higher, respectively, than the standard population. The odds of 
being admitted for the Post Traumatic group was 9 times higher with an average 
length of stay almost 4 days longer and total allowed claims dollars were 6 times 
higher than the standard population. Other cost and utilization measures produced 
similar results. CONCLUSIONS: Individuals experiencing seizures are expensive 
when compared to the standard population. The excess utilization is in manageable 
healthcare cost categories. By utilizing these novel groups, case managers may find 
new ways to manage patients with epilepsy, target interventions and measure the 
success of those interventions.
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OBJECTIVES: In 2011, PhilHealth, the Philippine national health insurance provider, 
switched to a case rate scheme in tandem with a policy which prevents govern-
67 clinical records were analyzed. The average cost per CHKV children patient was 
US$517.5 (US$756.9 in equal or older than 1 year old, and US$375.1 in under one 
year population). The average length of stay was 2,7 days per patient. More prescript 
drugs were oral rehydration salts and acetaminophen. The more requested labs were 
hematic chart (13.8%) and protein C reactive (7.57%). CONCLUSIONS: Despite CHKV 
infection is not a lethal disease, it would cause a very huge impact in the health 
services and it associated cost in Colombia. Cost per case in children is high, and 
probably would be similar or higher in adult population.
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OBJECTIVES: To determine the direct cost of health care technologies used for treat-
ment of hypothyroidism in Ukraine. METHODS: We made the retrospective analysis 
of 81 patients’s medical records with hypothyroidism that were hospitalized to 
the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). The 
method of pharmacoeconomic analysis “cost of illness” was used to estimate the 
cost of health care for patients with hypothyroidism. We have made calculations 
of costs: the cost of laboratory analysis, the cost of instrumental analysis, the cost 
of drug treatment, doctor’s consultations, costs of patient’s stay in hospital. While 
determining the direct costs of medical services in monetary terms we used the 
rates for medical services that were in Ternopil University Hospital. RESULTS: The 
study found that among the patients there were 23 (28.4%) men and 58 (71.6%) 
women aged 19 to 77 years (46.86±10.03). All patients have got to the hospital in 
stage of medication subcompensation. The average duration of stay in hospital for 
patients was 10.77±1.95 days. The total cost of laboratory tests was USD 4,231.95. The 
costs of instrumental methods of patients examination amounted USD 576.90. The 
cost of consultations by specialists was USD 769.36. In determining the amount of 
direct costs for medicines we found that the cost of drug treatment of the underlying 
disease was USD 52.40, the cost of drug therapy of hypothyroidism complications 
was USD 3,932.21. Total cost of patients stay in hospital was USD 9,411.80. After cal-
culation of all direct costs we determined that the total cost of hypothyroidism per 
patient is USD 234.26 per course of treatment. CONCLUSIONS: In the cost structure 
of health care provision for patients with hypothyroidism the most significant costs 
were spent for laboratory tests and for patient’s stay in hospital. The presence of 
underlying disease complications significantly increases cost of drugs.
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OBJECTIVES: To evaluate the clinical and economic impact of the incorporation of 
the monovalent conjugate vaccine against meningitis C caused by the Neisseria 
meningitides bacterium in children aged 0-4 years in the Brazilian public health 
system. METHODS: The analysis was developed for the period of 2009 to 2013. Were 
considered the actual number of cases of the disease recorded in the Notification 
Information System and deaths from meningitis C obtained from the Mortality 
Information System, and the estimates of long-term sequelae (amputation, skin 
scarring, renal failure, neurological sequelae and deafness) and of the costs due 
to sequelae, disease and vaccination. RESULTS: From 2009 to 2013, a decrease in 
the quantity of cases (684, 651, 563, 399 and 300, respectively) and in the number of 
deaths due to meningococcal meningitis (134, 111, 68, 61 and 47, respectively) was 
observed. There was also a reduction in the costs related with disease manage-
ment (R$ 1,572,632.28, R$ 1,496,759.67, R$ 1,294,432.71 and, R$ 917,368.83, respec-
tively) and with meningococcal meningitis sequelae (R$ 342,551.14, R$ 336,322.94, 
R$ 308,296.02, R$ 210,513.24 and, R$ 157,573.52, respectively). The three doses of 
the vaccine for children in their first year of life cost to the public treasury (R$ 
0.00, R$ 270,863,108.24, R$ 266,933,428.24, R$ 263,150,498.68 and, R$ 259,515,275.33, 
respectively). Therefore, the estimate of the value spent by the government in 
the evaluated years was R$ 1,915,183.42, R$ 272,696,190.85, R$ 268,536,156.97, R$ 
264,278,380.76 and, R$ 260,362,599.85. CONCLUSIONS: The Vaccine against menin-
gococcal meningitis type C implementation in SUS (Unique Health System - Sistema 
Único de Saúde in Portuguese) – the national public health system in Brazil – in 
infants in their first year of life generated reduction of incidence, mortality and 
sequelae due to the disease, decreasing, over the years, the cost due to the disease 
and to its sequelae, although adding the cost with vaccination.
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OBJECTIVES: To describe the prevalence of patient recall in the six months following 
traditional screening mammography and the related costs to Medicaid by patient 
race. METHODS: The Truven Health MarketScan Medicaid Multi-State Database was 
used to identify women aged 40-75 years undergoing screening mammography 
(index event) in 2010-2012. Women were required to have 12 months pre- and 6 
months post-index continuous enrollment and were excluded if they had mam-
mography or a breast cancer diagnosis in the 12 month pre-index period. Recall 
was defined as receipt of diagnostic mammogram or ultrasound in the six months 
following the index screen; patients with a subsequent breast cancer diagnosis were 
excluded from recall counts or costs. Payer cost per recall (2013 US$) was the sum 
of breast-related imagining and diagnostic procedures in the 6 months post-index, 
excluding patient payments and breast cancer treatment costs. RESULTS: A total of 
20,838 women undergoing a new screening mammogram met the study selection 
